Top Markets
#1 CyberDEX CyberDEX +391.95%
#2 OVERTAKE OVERTAKE +58.99%
#3 Clearpool Clearpool +25.94%
#4 Playnance Playnance +23.93%
#5 deBridge deBridge +22.97%
#6 B3 (Base) B3 (Base) +20.83%
#7 Nillion Nillion +19.56%
#8 AUKI AUKI +19.09%
#9 Codatta Codatta +17.25%
#10 龙虾 (Lobster) 龙虾 (Lobster) +17.03%
Coin of the day
CyberDEX CyberDEX
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Nuformix plc Nuformix plc

Nuformix plc

NFX
Kedudukan dalam Saham #41014
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes... Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
Harga Saham
$0.00185055
Modal Pasaran
$48.29K
Perubahan (1 hari)
-3.55%
Perubahan (1 tahun)
30.31%
Negara
GB
Perdagangan Nuformix plc (NFX)

Kategori

Healthcare
Nisbah P/E bagi Nuformix plc (NFX)
Nisbah P/E pada September 2026 TTM: -3.29
Menurut laporan kewangan dan harga saham terkini Nuformix plc, nisbah P/E semasa (TTM) ialah -3.29. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak -0.13.
Sejarah nisbah P/E bagi Nuformix plc dari 2014 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) -3.29 -44.95%
2025 -5.98 4,632.12%
2024 -0.13 -96.13%
2023 -3.26 -37.95%
2022 -5.26 -49.52%
2021 -10.42 -58.69%
2020 -25.23 249.86%
2019 -7.21 81.99%
2018 -3.96 -19.00%
2017 -4.89 26.79%
2016 -3.86 0.00%
2014 0.00 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.99 -1,011.14%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -18.38 458.39%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.34 608.91%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.30 -1,202.53%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.